These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 6718645)

  • 21. Venlafaxine in adults with attention-deficit/hyperactivity disorder: an open clinical trial.
    Findling RL; Schwartz MA; Flannery DJ; Manos MJ
    J Clin Psychiatry; 1996 May; 57(5):184-9. PubMed ID: 8626348
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An open trial of L-tyrosine in the treatment of attention deficit disorder, residual type.
    Reimherr FW; Wender PH; Wood DR; Ward M
    Am J Psychiatry; 1987 Aug; 144(8):1071-3. PubMed ID: 3300376
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reliability and validity of the SKAMP rating scale in a laboratory school setting.
    Wigal SB; Gupta S; Guinta D; Swanson JM
    Psychopharmacol Bull; 1998; 34(1):47-53. PubMed ID: 9564198
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The concordance between self-ratings of childhood and current symptoms of attention deficit hyperactivity disorder.
    Murphy P
    J Nerv Ment Dis; 2003 May; 191(5):341-3. PubMed ID: 12819555
    [No Abstract]   [Full Text] [Related]  

  • 25. Psychotherapy of attention deficit hyperactivity disorder in adults--a pilot study using a structured skills training program.
    Hesslinger B; Tebartz van Elst L; Nyberg E; Dykierek P; Richter H; Berner M; Ebert D
    Eur Arch Psychiatry Clin Neurosci; 2002 Aug; 252(4):177-84. PubMed ID: 12242579
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diagnosis and treatment of ADHD in adults in primary care.
    Montano B
    J Clin Psychiatry; 2004; 65 Suppl 3():18-21. PubMed ID: 15046531
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Atomoxetine and nonresponders to stimulants.
    Velcea G; Winsberg BG
    Am J Psychiatry; 2004 Sep; 161(9):1718-9. PubMed ID: 15337674
    [No Abstract]   [Full Text] [Related]  

  • 28. What is a significant response in drug studies of attention-deficit/hyperactivity disorder: statistical significance is necessary, but is it sufficient?
    Sangal RB; Sangal JM
    Psychopharmacol Bull; 2003; 37(2):50-8. PubMed ID: 14566214
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Disentangling deficits in adults with attention-deficit/hyperactivity disorder.
    Bekker EM; Overtoom CC; Kooij JJ; Buitelaar JK; Verbaten MN; Kenemans JL
    Arch Gen Psychiatry; 2005 Oct; 62(10):1129-36. PubMed ID: 16203958
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder.
    Spencer T; Biederman J; Wilens T; Doyle R; Surman C; Prince J; Mick E; Aleardi M; Herzig K; Faraone S
    Biol Psychiatry; 2005 Mar; 57(5):456-63. PubMed ID: 15737659
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Viewing preschool disruptive behavior disorders and attention-deficit/hyperactivity disorder through a developmental lens: what we know and what we need to know.
    Chacko A; Wakschlag L; Hill C; Danis B; Espy KA
    Child Adolesc Psychiatr Clin N Am; 2009 Jul; 18(3):627-43. PubMed ID: 19486842
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Attention deficit hyperactivity disorder in an adult].
    Sáiz Ruiz J; Ibáñez Cuadrado A; Diaz Marsá M
    Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1996; 24(3):135-40. PubMed ID: 8766450
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Double-blind, placebo-controlled study of zinc sulfate in the treatment of attention deficit hyperactivity disorder.
    Bilici M; Yildirim F; Kandil S; Bekaroğlu M; Yildirmiş S; Değer O; Ulgen M; Yildiran A; Aksu H
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Jan; 28(1):181-90. PubMed ID: 14687872
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gender effects on attention-deficit/hyperactivity disorder in adults, revisited.
    Biederman J; Faraone SV; Monuteaux MC; Bober M; Cadogen E
    Biol Psychiatry; 2004 Apr; 55(7):692-700. PubMed ID: 15038997
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder: a retrospective and prospective effectiveness study.
    Santosh PJ; Baird G; Pityaratstian N; Tavare E; Gringras P
    Child Care Health Dev; 2006 Sep; 32(5):575-83. PubMed ID: 16919137
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Amino acid precursors for the treatment of attention deficit disorder, residual type.
    Wood DR; Reimherr FW; Wender PH
    Psychopharmacol Bull; 1985; 21(1):146-9. PubMed ID: 3885291
    [No Abstract]   [Full Text] [Related]  

  • 37. [Schizophrenia and the minimal brain dysfunction syndrome].
    Dikiĭ NT
    Vrach Delo; 1986 Nov; (11):94-5. PubMed ID: 2881400
    [No Abstract]   [Full Text] [Related]  

  • 38. The prevalence of attention deficit disorder, residual type, or minimal brain dysfunction, in a population of male alcoholic patients.
    Wood D; Wender PH; Reimherr FW
    Am J Psychiatry; 1983 Jan; 140(1):95-8. PubMed ID: 6847993
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Is minimal brain dysfunction clinically irrelevant? Incredulous comments].
    Breiden U
    Z Kinder Jugendpsychiatr; 1989 Sep; 17(3):158-9; discussion 160-1. PubMed ID: 2800726
    [No Abstract]   [Full Text] [Related]  

  • 40. Attention deficit hyperactivity disorder in adults.
    Sachdev P
    Psychol Med; 1999 May; 29(3):507-14. PubMed ID: 10405073
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.